Indications : התוויות

4.1 Therapeutic indications
Malignant diseases:
Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment:
1. Malignant lymphomas (Stages III and IV of the Ann Arbor stagi g s ste ), Hodgki ’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s l phoma.
2. Multiple myeloma.
3. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children.
4. Mycosis fungoides (advanced disease).
5. Neuroblastoma (disseminated disease).
6. Adenocarcinoma of the ovary.
7. Retinoblastoma.
8. Carcinoma of the breast.
Nonmalignant Diseases:
Biopsy proven Minimal Change nephrotic syndrome in children whose disease fails to respond adequately to another treatment.
Severe cases of systemic Lupus Erythematoses which did not respond to other treatment, especially with nephritis.
Notes on conditioning prior to allogeneic bone marrow transplantation: 

Indication for bone marrow transplantation and thus for preceding conditioning therapy with Endoxan depends on a complex constellation of factors and must be decided on an individual basis. Significant factors include disease stage, prognosis (risk group), nature and success of previous treatments of the underlying disease, the patient's age and general condition as well as availability of a suitable bone marrow donor.
Special note:
If cystitis with micro- or macrohematuria occurs on treatment with Endoxan, the treatment should be discontinued until this condition normalizes.